| AEA | Anandamide |
| ALOGPS | Associative Logarithm of Partition Coefficient and Solubility |
| API | Approximal plaque index |
| ARTG | Australian Register of Therapeutic Goods |
| AQP3 | Aquaporin-3 |
| BACH1 | BTB domain and CNC Homology 1 |
| CBD | Cannabidiol |
| CB1 | Cannabinoid Receptor Type 1 |
| CB2 | Cannabinoid Receptor Type 2 |
| CBDA | Cannabidiolic acid |
| CBG | Cannabigerol |
| CBC | Cannabichromene |
| CBN | Cannabinol |
| DMSO | Dimethyl sulfoxide |
| DWC | Dermal water content |
| ECS | Endocannabinoid system |
| EMA | European Medicines Agency |
| EPA | Eicosapentaenoic acid |
| EU | European Union |
| FAAH | Fatty acid amide hydrolase |
| FDA | Food and Drug Administration |
| GCP | Good Clinical Practice |
| GMP | Good Manufacturing Practice |
| HMOX1 | Heme oxygenase 1 |
| IL | Interleukin |
| MAPK | Mitogen-Activated Protein Kinase |
| MITF | Microphthalmia-Associated Transcription Factor |
| MRSA | Methicillin-Resistant Staphylococcus aureus |
| NLCs | Nanostructured Lipid Carriers |
| Nrf2 | Nuclear Factor Erythroid 2–Related Factor 2 |
| PASI | Psoriasis Area and Severity Index |
| PEA | N-Palmitoylethanolamine |
| PPAR | Peroxisome Proliferator-Activated Receptor |
| ROS | Reactive Oxygen Species |
| SAS | Special Access Scheme |
| SLEB | Subepidermal Low-Echogenic Band |
| SNEDDS | Self-Nanoemulsifying Drug Delivery Systems |
| SOD | Superoxide Dismutase |
| TEWL | Transepidermal water loss |
| THC | Tetrahydrocannabinol |
| THCA | Tetrahydrocannabinolic acid |
| THCV | Tetrahydrocannabivarin |
| TRP | Transient receptor potential |
| TRPA | Transient receptor potential ankyrin |
| TRPV | Transient receptor potential vanilloid |
| UK | United Kingdom |
| USA | United States of America |
| VEGF | Vascular Endothelial Growth Factor |
| VRSA | Vancomycin-resistant Staphylococcus aureus |